Drug-Induced Liver Injury: Clinical Evidence of N-Acetyl Cysteine Protective Effects.
Level 5 - mechanism / opinion, no new human data
Narrative review of pathophysiological mechanisms and clinical literature without systematic review methodology
PubMed 34912495 · doi:10.1155/2021/3320325
What was done
This narrative review synthesized literature on the pathophysiological mechanisms of oxidative stress in drug-induced liver injury (DILI) and evaluated clinical evidence regarding the therapeutic and protective role of N-acetyl cysteine (NAC), including its application in paracetamol- and non-paracetamol-induced liver injury.
What was found
The abstract reports no quantitative data or effect sizes. Qualitatively, it notes that NAC counteracts mitochondrial oxidative stress and metabolic abnormalities by enhancing endogenous glutathione (GSH) levels, reducing patient mortality in DILI, and decreasing toxicity biomarkers such as keratin-18 and circulating caspase-cleaved cytokeratin-18. It also notes potential benefits in non-paracetamol liver injuries such as excessive alcohol intake, but highlights a lack of evidence for combination therapies.
Why it matters
It provides a mechanistic overview of how NAC mitigates DILI beyond classical paracetamol toxicity while outlining current boundaries in combination treatment strategies.
Limits
The abstract does not describe a systematic search strategy, selection criteria, or quantitative meta-analysis. No specific patient counts, clinical trial metrics, effect sizes, or risk-of-bias evaluations are provided.
Cited by
- supports N-acetylcysteine (NAC) acts as the antidote to acetaminophen (Tylenol) hepatotoxicity by restoring depleted glutathione levels.